Immunomodulators are agents that alter a pathway controlling the activity of the immune system. Immune checkpoint inhibitors are immunotherapies employed as a novel treatment for various cancers, including metastatic melanoma, Hodgkin lymphoma, breast cancer, and non-small cell lung cancer, each carrying high morbidity and mortality in the setting of limited therapeutic options. Despite promising outcomes for cancer treatment, immune checkpoint inhibitors can cross-react with cells of the endocrine system and potentially cause serious endocrine immune-related adverse events. Patients undergoing treatment with immune checkpoint inhibitors may develop various endocrinopathies, including hypophysitis, thyroiditis, adrenal insufficiency, insulin-dependent diabetes, and calcium derangements. Specific autoantibodies may play a role in the susceptibility of a patient to this cross-reactivity. Specialized evaluation and management of endocrinopathies with hormone replacement therapy or suppression is imperative to guarantee the best possible outcomes for affected patients. Long-term monitoring and treatment guided by an endocrinologist is usually indicated.This activity reviews the possible pathophysiology of immune checkpoint inhibitor-induced endocrinopathies, the epidemiology of these adverse events, and specific evaluation and management of the hormonal axes involved. The activity also highlights the role of the interprofessional, multidisciplinary team required to care for patients with immunomodulator-induced endocrine disorders.
- Provider:StatPearls, LLC
- Activity Link: https://www.statpearls.com/ArticleLibrary/viewarticle/149534
- Start Date: 2023-09-01 05:00:00
- End Date: 2023-09-01 05:00:00
- Credit Details: IPCE Credits: 1.0 hours
AMA PRA Category 1 Credit™️: 1.0 hours
Nursing: 1.0 hours
Pharmacy: 1.0 hours - MOC Credit Details: ABS - 1.0 Point; Credit Type(s): Accredited CME (ABS)
ABOS - 1.0 Point; Credit Type(s): Accredited CME (ABOS)
ABPATH - 1.0 Point; Credit Type(s): Lifelong Learning (ABPATH)
ABTS - 1.0 Point; Credit Type(s): Accredited CME (ABTS)
ABIM - 1.0 Point; Credit Type(s): Medical Knowledge (ABIM)
ABS - 1.0 Point; Credit Type(s): Self-Assessment (ABS)
ABP - 1.0 Point; Credit Type(s): Lifelong Learning and Self-Assessment (ABP)
ABTS - 1.0 Point; Credit Type(s): Self-Assessment (ABTS)
ABIM - 1.0 Point; Credit Type(s): Patient Safety (ABIM)
ABTS - 1.0 Point; Credit Type(s): Patient Safety (ABTS) - Commercial Support: No
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: Variable
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: Complex General Surgical Oncology, Endocrine, Endocrinology, Diabetes, and Metabolism, General Thoracic, Medical Oncology, Musculoskeletal Oncology, Non-Thoracic Surgery, Pediatric Endocrinology, Pediatric Hematology-Oncology